Cyclodextrin-based controlled drug release system.
暂无分享,去创建一个
F. Hirayama | K. Uekama | Uekama | Hirayama
[1] F. Hirayama,et al. Improvement of stability and dissolution of prostaglandin E1 by maltosyl-beta-cyclodextrin in lyophilized formulation. , 1992, Chemical & pharmaceutical bulletin.
[2] T. Nadai,et al. Sustained release of flufenamic acid from a drug-triacetyl-beta-cyclodextrin complex. , 1997, Biological and Pharmaceutical Bulletin.
[3] F. Hirayama,et al. Some physicochemical properties of branched β-cyclodextrins and their inclusion characteristics , 1989 .
[4] I. Habuš,et al. Synthesis, hybridization properties, nuclease stability, and cellular uptake of the oligonucleotide--amino-beta-cyclodextrins and adamantane conjugates. , 1995, Bioconjugate chemistry.
[5] I. Miwa,et al. Kinetic difference between hydrolyses of γ-cyclodextrin by human salivary and pancreatic α-amylases , 1981 .
[6] K. Uekama,et al. Combination effects of O-carboxymethyl-O-ethyl-β-cyclodextrin and penetration enhancer HPE-101 on transdermal delivery of prostaglandin E1 in hairless mice , 1993 .
[7] A. Coleman,et al. New β-cyclodextrin derivatives possessing biologically active saccharide antennae , 1993 .
[8] R. Horváth,et al. A new approach to enhance bioavailability of biologically active peptides: conjugation of a δ opioid agonist to β-cyclodextrin , 1993 .
[9] G. Müller,et al. Cyclodextrin as Carrier of Peptide Hormones. Conformational and Biological Properties of β-Cyclodextrin/Gastrin Constructs , 1998 .
[10] J. L. Vila-jato,et al. Preparation and evaluation of ketoconazole-β-cyclodextrin multicomponent complexes , 1996 .
[11] F. Hirayama,et al. Cyclodextrin Drug Carrier Systems. , 1998, Chemical reviews.
[12] T. Loftsson. Pharmaceutical applications of β-cyclodextrin , 1999 .
[13] F. Hirayama,et al. In‐vitro Evaluation of Biphenylyl Acetic Acid‐β‐Cyclodextrin Conjugates as Colon‐targeting Prodrugs: Drug Release Behaviour in Rat Biological Media , 1996, The Journal of pharmacy and pharmacology.
[14] Osama A. Soliman,et al. Amorphous spironolactone-hydroxypropylated cyclodextrin complexes with superior dissolution and oral bioavailability , 1997 .
[15] E. Anaissie,et al. γ-cyclodextrin: Testosterone complex suitable for sublingual administration , 1987 .
[16] F. Hirayama,et al. In‐vivo and In‐vitro Correlation for Delayed‐release Behaviour of a Molsidomine/O‐carboxymethyl‐O‐ethyl‐β‐cyclodextrin Complex in Gastric Acidity‐controlled Dogs , 1995, The Journal of pharmacy and pharmacology.
[17] F. Hirayama,et al. Release Characteristics of Nifedipine from 2-Hydroxypropyl-β-cyclodextrin Complex during Storage and Its Modification of Hybridizing Polyvinylpyrrolidone K-30 , 1993 .
[18] F. Hirayama,et al. Peracylated β‐Cyclodextrins as Novel Sustained‐release Carriers for a Water‐soluble Drug, Molsidomine , 1994, The Journal of pharmacy and pharmacology.
[19] T Nadai,et al. Effect of the interaction of drug-beta-cyclodextrin complex with bile salts on the drug absorption from rat small intestinal lumen. , 1989, Chemical & pharmaceutical bulletin.
[20] K. Hattori,et al. The specificity of association between concanavalin a and oligosaccharide-branched cyclodextrins with an optical biosensor , 1997 .
[21] F. Hirayama,et al. Ethylated beta-cyclodextrins as hydrophobic drug carriers: sustained release of diltiazem in the rat. , 1987, Journal of pharmaceutical sciences.
[22] D. Begley,et al. The Blood‐brain Barrier: Principles for Targeting Peptides and Drugs to the Central Nervous System , 1996, The Journal of pharmacy and pharmacology.
[23] B. Müller,et al. Cyclodextrin derivatives in pharmaceutics. , 1995, Critical reviews in therapeutic drug carrier systems.
[24] M. Skiba,et al. Evaluation of gastrointestinal behaviour in the rat of amphiphilic β-cyclodextrin nanocapsules, loaded with indomethacin , 1995 .
[25] N. Bodor,et al. Brain-enhanced delivery of testosterone using a chemical delivery system complexed with 2-hydroxypropyl-beta-cyclodextrin. , 1988, Drug design and delivery.
[26] D. Morré,et al. Impermeant antitumor sulfonylurea conjugates that inhibit plasma membrane NADH oxidase and growth of HeLa cells in culture. Identification of binding proteins from sera of cancer patients. , 1997, Biochimica et biophysica acta.
[27] F. Djedaïni-Pilard,et al. Synthesis of a new molecular carrier: N-(Leu-enkephalin)yl 6-amido-6-deoxy-cyclomaltoheptaose , 1993 .
[28] F. Hirayama,et al. Inhibitory Effect of 2‐Hydroxypropyl‐β‐cyclodextrin on Crystal‐growth of Nifedipine During Storage: Superior Dissolution and Oral Bioavailability Compared with Polyvinylpyrrolidone K‐30 , 1992, The Journal of pharmacy and pharmacology.
[29] F. Hirayama. [Development and pharmaceutical evaluation of hydrophobic cyclodextrin derivatives as modified-release drug carriers]. , 1993, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.
[30] K. Uekama,et al. Controlled release of the LHRH agonist buserelin acetate from injectable suspensions containing triacetylated cyclodextrins in an oil vehicle , 1994 .
[31] Michael Szycher,et al. High performance biomaterials : a comprehensive guide to medical and pharmaceutical applications , 1992 .
[32] F. Hirayama,et al. In vitro and in vivo evaluation of delayed-release behavior of diltiazem from its O-carboxymethyl-O-ethyl-β-cyclodextrin complex , 1993 .
[33] T. Loftsson,et al. Design and in vivo testing of 17β-estradiol-HPβCD sublingual tablets , 1996 .
[34] J. Pitha,et al. Hydrophilic cyclodextrin derivatives enable effective oral administration of steroidal hormones. , 1986, Journal of pharmaceutical sciences.
[35] F. Hirayama,et al. Release control of theophylline by β-cyclodextrin derivatives: hybridizing effect of hydrophilic, hydrophobic and ionizable β-cyclodextrin complexes , 1991 .
[36] A. Coleman,et al. Chemical–enzymatic synthesis and bioactivity of mono-6-[Gal-β-1,4-GlcNAc-β-(1,6′)-hexyl]amido-6-deoxy-cycloheptaamylose , 1995 .
[37] D. Friend. Oral Colon-Specific Drug Delivery , 1992 .
[38] F. Hirayama,et al. Utilization of Diethyl-β-Cyclodextin as a Sustained-Release Carrier for Isosorbide Dinitrate , 1988 .
[39] H. Parrot-Lopez,et al. Recognition ability and cytotoxicity of some oligosaccharidylsubstituted β-cyclodextrins , 1994, Biology of the Cell.
[40] D O Thompson,et al. Cyclodextrins--enabling excipients: their present and future use in pharmaceuticals. , 1997, Critical reviews in therapeutic drug carrier systems.
[41] F. Hirayama,et al. Design and In‐vitro Evaluation of a Modified‐release Oral Dosage Form of Nifedipine by Hybridization of Hydroxypropyl‐β‐cyclodextrin and Hydroxypropylcellulose , 1993, The Journal of pharmacy and pharmacology.
[42] K. Uekama,et al. Pharmaceutical evaluation of hydroxyalkyl ethers of β-cyclodextrins , 1988 .
[43] Hans Bundgaard,et al. Design of prodrugs , 1985 .
[44] K. Koizumi,et al. Isolation and characterization of branched cyclodextrins , 1986 .
[45] B. Müller,et al. Solubilization of drugs by modified β-cyclodextrins , 1985 .
[46] V. Stella,et al. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. , 1996, Journal of pharmaceutical sciences.
[47] S. Yen,et al. Sublingual administration of testosterone-hydroxypropyl-beta-cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men. , 1991, The Journal of clinical endocrinology and metabolism.
[48] Fumitoshi Hirayama,et al. Enhanced Bioavailability and Reduced Metabolism of Salbutamol by Perbutanoyl-β-cyclodextrin after Oral Administration in Dogs , 1995 .
[49] K. Uekama. [Pharmaceutical applications of cyclodextrin complexations (author's transl)]. , 1981, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.
[50] R. Okamoto,et al. Synthesis of doxorubicin-cyclodextrin conjugates. , 1994, The Journal of antibiotics.
[51] N. Bodor,et al. Development of aqueous parenteral formulations for carbamazepine through the use of modified cyclodextrins. , 1991, Journal of pharmaceutical sciences.
[52] A. Larsen,et al. An econazole β-cyclodextrin inclusion complex: an unusual dissolution rate, supersaturation, and biological efficacy example , 1998 .
[53] N. Bodor,et al. The potential use of cyclodextrins in parenteral formulations. , 1989, Journal of parenteral science and technology : a publication of the Parenteral Drug Association.
[54] R. Hancock,et al. Synthesis of bulky beta-lactams for inhibition of cell surface beta-lactamase activity. , 1993, Bioconjugate chemistry.
[55] K. Himmelstein,et al. Osmotic flow through controlled porosity films: An approach to delivery of water soluble compounds , 1985 .
[56] N. Bodor,et al. Improved delivery through biological membranes. XXXL: Solubilization and stabilization of an estradiol chemical delivery system by modified beta-cyclodextrins. , 1988, Journal of pharmaceutical sciences.
[57] N. Bodor,et al. Oral pharmacokinetics of carbamazepine in dogs from commercial tablets and a cyclodextrin complex. , 1993, Journal of pharmaceutical sciences.
[58] F. Hirayama,et al. Acid-catalyzed hydrolysis of maltosyl-β-cyclodextrin , 1992 .
[59] F. Schuit,et al. Genetic susceptibility for insulin-dependent diabetes mellitus in Caucasians revisited: the importance of diabetes registries in disclosing interactions between HLA-DQ- and insulin gene-linked risk. Belgian Diabetes Registry. , 1995, The Journal of clinical endocrinology and metabolism.
[60] F. Hirayama,et al. Slow-release characteristics of diltiazem from ethylated beta-cyclodextrin complexes. , 1990, Journal of pharmaceutical sciences.
[61] M. Brewster,et al. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. , 1996, Journal of pharmaceutical sciences.
[62] J. Pitha. Amorphous water-soluble derivatives of cyclodextrins: nontoxic dissolution enhancing excipients. , 1985, Journal of pharmaceutical sciences.
[63] F. Hirayama,et al. 6A-O-[(4-Biphenylyl)acetyl]-α-, -β-, and -γ-cyclodextrins and 6A-deoxy-6A-[[(4-biphenylyl)acetyl]amino] -α-, -β-, and -γ-cyclodextrins : Potential prodrugs for colon-specific delivery , 1997 .
[64] F. Hirayama,et al. Improvement of the oral bioavailability of digitalis glycosides by cyclodextrin complexation. , 1983, Journal of pharmaceutical sciences.
[65] Y Horiuchi,et al. Design and in vitro evaluation of slow-release dosage form of piretanide: utility of beta-cyclodextrin:cellulose derivative combination as a modified-release drug carrier. , 1990, Journal of pharmaceutical sciences.
[66] F. Hirayama,et al. Colon-specific drug delivery based on a cyclodextrin prodrug: release behavior of biphenylylacetic acid from its cyclodextrin conjugates in rat intestinal tracts after oral administration. , 1998, Journal of pharmaceutical sciences.
[67] K. Uekama,et al. Sustained release of buserelin acetate, a luteinizing hormone‐releasing hormone agonist, from an injectable oily preparation utilizing ethylated β‐cyclodextrin , 1989, The Journal of pharmacy and pharmacology.
[68] K. Uekama,et al. Cyclodextrins in drug carrier systems. , 1987, Critical reviews in therapeutic drug carrier systems.
[69] K. Uekama,et al. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. , 1997, Journal of pharmaceutical sciences.
[70] H. Brøndsted,et al. Current applications of polysaccharides in colon targeting. , 1996, Critical reviews in therapeutic drug carrier systems.
[71] F. Hirayama,et al. Crystallization and polymorphic transition behavior of chloramphenicol palmitate in 2-hydroxypropyl-β-cyclodextrin matrix , 1997 .
[72] Jean-Marie Lehn,et al. Comprehensive Supramolecular Chemistry , 1996 .
[73] F. Hirayama,et al. O-carboxymethyl-O-ethylcyclomaltoheptaose as a delayed-release-type drug carrier: improvement of the oral bioavailability of diltiazem in the dog. , 1989, Carbohydrate research.
[74] N. Bodor,et al. Redox Drug Delivery Systems for Targeting Drugs to the Brain a , 1987, Annals of the New York Academy of Sciences.
[75] Valentino J. Stella,et al. β‐Cyclodextrin Derivatives, SBE4‐β‐CD and HP–β‐CD, Increase the Oral Bioavailability of Cinnarizine in Beagle Dogs , 1995 .